% | $
Quotes you view appear here for quick access.

Zalicus AŞ Message Board

  • bigbro79 bigbro79 Mar 19, 2013 8:12 AM Flag

    Zalicus Inc : Zalicus Presents Data Demonstrating Advantages of State-Dependent Ion Channel Screening

    Utility of Inactivation State Screening for the Identification of Novel Pain Therapies Presented at RSC/SCI Symposium on Ion Channels as Therapeutic Targets Conference

    Zalicus Inc. (Nasdaq Global Market: ZLCS) today announced that preclinical data showing the advantages of applying Zalicus's state dependent screening approach to identify novel calcium channel blockers for the treatment of pain was presented on March 18 at the 4th Annual RSC/SCI Symposium on Ion Channels as Therapeutic Targets Conference taking place from March 18-19, 2013 in Cambridge, UK.

    In a poster presentation entitled "Screening for State-Dependent Blockers of Voltage Gated Calcium Channels," Margaret S. Lee, PhD, Vice President of Research & Translational Medicine at Zalicus, demonstrated the utility of inactivation state screening to identify novel, potent, selective and state-dependent calcium channel blockers with efficacy in animal models of inflammatory and neuropathic pain.

    "Rapid neuronal firing which occurs during chronic pathological pain results in accumulation of voltage gated calcium channels in an inactivated state. By specifically targeting this inactivated state of these channels, it may be possible to broaden the therapeutic window, minimize adverse effects and increase efficacy for these promising pain therapies," said Dr. Lee. "Comparative screening in our cell based assays for state dependent modulation of ion channel function has resulted in the discovery of Z160 and Z944, Zalicus's two most advanced novel, first-in-class calcium channel blockers. Both Z160 and Z944 have effectively demonstrated enhanced potency for their respective targets in the inactivated state."

    SortNewest  |  Oldest  |  Most Replied Expand all replies